RESUMEN
RATIONALE: Two new certified reference materials (CRMs) have been prepared providing three steroids certified for stable carbon isotope delta values, δ(13 C) . These materials have been designed to assist anti-doping laboratories in validating their calibration method or to be employed as calibrant for stable carbon isotope measurements of Boldenone, Boldenone Metabolite 1 and Formestane. These CRMs will allow for accurate and traceable analysis in compliance with World Anti-Doping Agency (WADA) Technical Document TD2021IRMS. METHODS: Certification was performed using an elemental analyser-isotope ratio mass spectrometry (EA-IRMS) primary reference method on the bulk carbon isotope ratios of nominally pure steroid starting materials. EA-IRMS analyses were carried out on a Flash EA Isolink CN coupled via a Conflo IV to a Delta V plus mass spectrometer. Confirmation analysis was performed by gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) using a Trace 1310 GC coupled to a Delta V plus mass spectrometer via GC Isolink II. RESULTS: Based on the EA-IRMS analysis, the materials were certified with δ(13 C) values of -30.38 (Boldenone), -29.71 (Boldenone Metabolite 1) and 30.71 (Formestane). Noting that the assumption of 100% purity in the starting materials has the potential to introduce bias, this was investigated using GC-C-IRMS analysis and theoretical modelling based on purity assessment data. CONCLUSIONS: Careful application of this theoretical model was shown to provide reasonable estimates of uncertainty while avoiding the introduction of errors associated with analyte-specific fractionation during GC-C-IRMS analysis.
Asunto(s)
Esteroides , Isótopos de Carbono/análisis , Cromatografía de Gases y Espectrometría de Masas/métodos , Espectrometría de Masas/métodos , CalibraciónRESUMEN
Endometriosis, a painful gynecological condition accompanied by inflammation in women of reproductive age, is associated with an increased risk of ovarian cancer. We evaluated the role of peritoneal heme accumulated during menstrual cycling, as well as peritoneal and lesional macrophage phenotype, in promoting an oncogenic microenvironment. We quantified the heme-degrading enzyme, heme oxygenase-1 (HO-1, encoded by Hmox1) in normal peritoneum, endometriotic lesions and endometriosis-associated ovarian cancer (EAOC) of clear cell type (OCCC). HO-1 was expressed primarily in macrophages and increased in endometrioma and OCCC tissues relative to endometriosis and controls. Further, we compared cytokine expression profiles in peritoneal macrophages (PM) and peripheral blood mononuclear cells (PBMC) in women with endometriosis versus controls as a measure of a tumor-promoting environment in the peritoneum. We found elevated levels of HO-1 along with IL-10 and the pro-inflammatory cytokines (IL-1ß, IL-16, IFNγ) in PM but not in PBMC from endometriosis patients. Using LysM-Cre:Hmox1flfl conditional knockout mice, we show that a deficiency of HO-1 in macrophages led to the suppression of growth of ID8 ovarian tumors implanted into the peritoneum. The restriction of ID8 ovarian tumor growth was associated with an increased number of Mac3+ macrophage and B cells in LysM-Cre:Hmox1flfl mice compared to controls. Functional experiments in ovarian cancer cell lines show that HO-1 is induced by heme. Low levels of exogenous heme promoted ovarian cancer colony growth in soft agar. Higher doses of heme led to slower cancer cell colony growth in soft agar and the induction of HO-1. These data suggest that perturbation of heme metabolism within the endometriotic niche and in cancer cells themselves may be an important factor that influences tumor initiation and growth.
RESUMEN
INTRODUCTION: Enhanced recovery after surgery (ERAS) pathways combine a comprehensive set of peri-operative practices that have been demonstrated to hasten patient post-operative recovery. We aimed to evaluate the adoption of ERAS components and assess attitudes towards ERAS among gynecologic oncologists. METHODS: We developed and administered a cross-sectional survey of attending, fellow, and resident physicians who were members of the Society of Gynecologic Oncology in January 2018. The χ2 test was used to compare adherence to individual components of ERAS. RESULTS: There was a 23% survey response rate and we analyzed 289 responses: 79% were attending physicians, 57% were from academic institutions, and 64% were from institutions with an established ERAS pathway. Respondents from ERAS institutions were significantly more likely to adhere to recommendations regarding pre-operative fasting for liquids (ERAS 51%, non-ERAS 28%; p<0.001), carbohydrate loading (63% vs 16%; p<0.001), intra-operative fluid management (78% vs 32%; p<0.001), and extended duration of deep vein thrombosis prophylaxis for malignancy (69% vs 55%; p=0.003). We found no difference in the use of mechanical bowel preparation, use of peritoneal drainage, or use of nasogastric tubes between ERAS and non-ERAS institutions. Nearly all respondents (92%) felt that ERAS pathways were safe. DISCUSSION: Practicing at an institution with an ERAS pathway increased adoption of many ERAS elements; however, adherence to certain guidelines remains highly variable. Use of bowel preparation, nasogastric tubes, and peritoneal drainage catheters remain common. Future work should identify barriers to the implementation of ERAS and its components.
Asunto(s)
Recuperación Mejorada Después de la Cirugía , Neoplasias de los Genitales Femeninos/cirugía , Procedimientos Quirúrgicos Ginecológicos/normas , Laparoscopía/normas , Oncólogos/normas , Actitud del Personal de Salud , Estudios Transversales , Femenino , Adhesión a Directriz , Procedimientos Quirúrgicos Ginecológicos/métodos , Procedimientos Quirúrgicos Ginecológicos/psicología , Humanos , Laparoscopía/métodos , Laparoscopía/psicología , Oncólogos/psicología , Encuestas y CuestionariosRESUMEN
OBJECTIVES: Financial toxicity is increasingly recognized as an adverse outcome of cancer treatment. Our objective was to measure financial toxicity among gynecologic oncology patients and its association with demographic and disease-related characteristics; self-reported overall health; and cost-coping strategies. METHODS: Follow-up patients at a gynecologic oncology practice completed a survey including the COmprehensive Score for Financial Toxicity (COST) tool and a self-reported overall health assessment, the EQ-VAS. We abstracted disease and treatment characteristics from medical records. We dichotomized COST scores into low and high financial toxicity and assessed the correlation (r) between COST scores and self-reported health. We calculated risk ratios (RR) and 95% confidence intervals (CI) for the associations of demographic and disease-related characteristics with high financial toxicity, as well as the associations between high financial toxicity and cost-coping strategies. RESULTS: Among 240 respondents, median COST score was 29. Greater financial toxicity was correlated with worse self-reported health (râ¯=â¯0.47; pâ¯<â¯0.001). In the crude analysis, Black or Hispanic race/ethnicity, government-sponsored health insurance, lower income, unemployment, cervical cancer and treatment with chemotherapy were associated with high financial toxicity. In the multivariable analysis, only government-sponsored health insurance, lower income, and treatment with chemotherapy were significantly associated with high financial toxicity. High financial toxicity was significantly associated with all cost-coping strategies, including delaying or avoiding care (RR: 7.3; 95% CI: 2.8-19.1). CONCLUSIONS: Among highly-insured gynecologic oncology patients, many respondents reported high levels of financial toxicity. High financial toxicity was significantly associated with worse self-reported overall health and cost-coping strategies, including delaying or avoiding care.
Asunto(s)
Costo de Enfermedad , Financiación Personal/estadística & datos numéricos , Neoplasias de los Genitales Femeninos/economía , Gastos en Salud/estadística & datos numéricos , Aceptación de la Atención de Salud/estadística & datos numéricos , Adaptación Psicológica , Adulto , Anciano , Estudios Transversales , Femenino , Financiación Personal/economía , Estudios de Seguimiento , Neoplasias de los Genitales Femeninos/diagnóstico , Neoplasias de los Genitales Femeninos/terapia , Humanos , Renta/estadística & datos numéricos , Seguro de Salud/economía , Seguro de Salud/estadística & datos numéricos , Persona de Mediana Edad , Aceptación de la Atención de Salud/psicología , Autoinforme/estadística & datos numéricos , Factores de Tiempo , Tiempo de TratamientoRESUMEN
OBJECTIVES: Gynecologic malignancies are the leading cause of cancer death among women in Botswana. Twenty-five percent of cervical cancers present at a stage that could be surgically cured; however, there are no gynecologic oncologists to provide radical surgeries. A sustainable model for delivery of advanced surgery is essential to advance treatment for gynecologic malignancies. METHODS/MATERIALS: A model was developed to provide gynecologic oncology surgery in Botswana, delivered by US-based gynecologic oncologists in four 2-week blocks per year. A pilot gynecologic oncology campaign was planned at a district hospital. Eligible patients were identified through the gynecologic oncology multidisciplinary clinic at the regional referral hospital, where gynecologic oncology treatment planning is provided. Local providers were invited to participate to build local surgical capacity. RESULTS: One US-based gynecologic oncologist, 2 gynecologists, and 2 surgeons working in Botswana participated in the pilot campaign. Sixteen operations were performed over 7 days. Indications included cervical cancer (4), ovarian cancer (3), vulvar cancer (1), complex atypical hyperplasia (1), pre-invasive cervical disease (2), and benign disease (3), as well as 2 obstetric emergencies. The only gynecologic oncology complication was a case of bleeding requiring transfusion and postoperative intensive care unit admission. Follow-up care was coordinated through the gynecologic oncology multidisciplinary clinic. CONCLUSIONS: Periodic gynecologic oncology campaigns in settings otherwise lacking local capacity to perform advanced surgery are a feasible model to create access and build local capacity. Strong local collaboration is essential. Future strategies to increase impact include recruitment of more gynecologic oncologists to increase service and training availability.
Asunto(s)
Neoplasias de los Genitales Femeninos/cirugía , Ginecología/organización & administración , Oncología Quirúrgica/organización & administración , Adolescente , Adulto , Botswana , Países en Desarrollo , Femenino , Ginecología/métodos , Humanos , Persona de Mediana Edad , Modelos Organizacionales , Proyectos Piloto , Oncología Quirúrgica/métodos , Adulto JovenRESUMEN
â¢Gynecologic oncologists face multiple barriers in participating in global health.â¢Several barriers may be addressed at the institutional level.â¢Most global health experiences involved direct patient care, while only a small proportion involved research.â¢Gynecologic oncologists receive little structured training in global health.
RESUMEN
â¢Ovarian cancer of Mullerian origin may have paraneoplastic features as a first presenting symptom.â¢Presentations of polymyositis may be associated with underlying carcinomas of Mullerian origin.â¢Our patient demonstrated clinical improvement in symptoms after initiation of steroids, IVIG and chemotherapy.
RESUMEN
Congenital adrenal hyperplasia (CAH) is an inherited disorder of adrenal steroidogenesis often diagnosed in infancy. Gynecologists may encounter adult patients with CAH due to the clinical effects of increased androgens, e.g. hirsutism, clitoromegaly, oligomenorrhea, or, rarely, pelvic masses. This case report reviews the association of para-ovarian adrenal rest tumors with CAH, and the role of gynecologists in their evaluation and treatment. A 23-year-old woman with CAH (21-hydroxyase deficiency) untreated for the past 5 years presented with a pelvic mass and elevated serum testosterone (1433 ng/dL) and plasma ACTH (1117 pg/mL). Intraoperative findings revealed multiple retroperitoneal masses. Final pathology demonstrated adrenal rest tissue. Para-ovarian and ovarian adrenal rest tumors may present as a rare gynecologic manifestation in patients with untreated CAH.
Asunto(s)
Anexos Uterinos/patología , Enfermedades de los Anexos/patología , Hiperplasia Suprarrenal Congénita/complicaciones , Tumor de Resto Suprarrenal/patología , Neoplasias Retroperitoneales/patología , Enfermedades de los Anexos/diagnóstico por imagen , Enfermedades de los Anexos/etiología , Tumor de Resto Suprarrenal/diagnóstico por imagen , Tumor de Resto Suprarrenal/etiología , Femenino , Humanos , Neoplasias Retroperitoneales/diagnóstico por imagen , Neoplasias Retroperitoneales/etiología , Adulto JovenRESUMEN
OPINION STATEMENT: Inhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as a new class of anti-cancer drugs, specifically for malignancies bearing aberrations of the homologous recombination pathway, like those with mutations in the BRCA 1 and BRCA 2 genes. Olaparib, a potent PARP1 and PARP2 inhibitor, has been shown to significantly increase progression-free survival (PFS) in women with recurrent ovarian cancer related to a germline BRCA mutation and is currently approved fourth-line treatment in these patients. PARP inhibitors (PARPi) target the genetic phenomenon known as synthetic lethality to exploit faulty DNA repair mechanisms. While ovarian cancer is enriched with a population of tumors with known homologous recombination defects, investigations are underway to help identify pathways in other gynecologic cancers that may demonstrate susceptibility to PARPi through synthetically lethal mechanisms. The ARIEL2 trial prospectively determined a predictive assay to identify patients with HRD. The future of cancer therapeutics will likely incorporate these HRD assays to determine the best treatment plan for patients. While the role of PARPi is less clear in non-ovarian gynecologic cancers, the discovery of a predictive assay for HRD may open the door for clinical trials in these other gynecologic cancers enriched with patients with HRD. Identification of patients with tumors deficient in homologous repair or have HRD-like behavior moves cancer treatment towards individualized therapies in order to maximize treatment effect and quality of life for women living with gynecologic cancers.
Asunto(s)
Neoplasias de los Genitales Femeninos/tratamiento farmacológico , Neoplasias Ováricas/tratamiento farmacológico , Ftalazinas/administración & dosificación , Piperazinas/administración & dosificación , Inhibidores de Poli(ADP-Ribosa) Polimerasas/administración & dosificación , Proteína BRCA1/genética , Proteína BRCA2/genética , Reparación del ADN/efectos de los fármacos , Supervivencia sin Enfermedad , Femenino , Neoplasias de los Genitales Femeninos/genética , Neoplasias de los Genitales Femeninos/patología , Recombinación Homóloga/genética , Humanos , Neoplasias Ováricas/genética , Neoplasias Ováricas/patología , Poli(ADP-Ribosa) Polimerasa-1/antagonistas & inhibidores , Poli(ADP-Ribosa) Polimerasas/efectos de los fármacos , Mutaciones Letales Sintéticas/genéticaRESUMEN
Anti-angiogenic agents are an important adjuvant treatment strategy in gynecologic cancer. Bevacizumab was recently approved for use in advanced cervical cancer and platinum-resistant ovarian cancer. The overall survival advantage bevacizumab confers in advanced cervical cancer prompted a paradigm shift in the standard of care for this disease. Because many other therapeutic options are available, and because of the heterogeneity of ovarian malignancies, the best combination of chemotherapeutics and bevacizumab has yet to be determined; studies are on-going. The utility of bevacizumab in uterine cancer has not been consistently demonstrated; current studies are limited to early-phase clinical trials. Other anti-angiogenic agents, including oral therapies for cervical and ovarian cancers, are under investigation; this therapeutic class of drugs appears promising.
Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Neoplasias de los Genitales Femeninos/tratamiento farmacológico , Ensayos Clínicos como Asunto , Femenino , Neoplasias de los Genitales Femeninos/mortalidad , HumanosRESUMEN
OBJECTIVE: Investigate the impact of socioeconomic status and other demographic variables on adherence to the National Comprehensive Cancer Network ovarian cancer treatment guidelines among patients with stage I/II disease. METHODS: Patients diagnosed with stage I/II epithelial ovarian cancer between 1/1/96-12/31/06 were identified from the California Cancer Registry. Univariate analysis and multivariate logistic regression models were used to evaluate differences in surgical procedures, chemotherapy regimens, and overall adherence to the NCCN guidelines according to increasing SES quintiles (SES-1 to SES-5). RESULTS: A total of 5445 stage I and II patients were identified. The median age at diagnosis was 54.0years (range=18-99years); 72.5% of patients had stage I disease, while 27.5% had stage II disease. With a median follow-up time of 5years, the 5-year ovarian cancer-specific survival for all patients was 82.7% (SE=0.6%). Overall, 23.7% of patients received care that was adherent to the NCCN guidelines. Compared to patients in the highest SES quintile (SES-5), patients in the lowest SES quintile (SES-1) were significantly less likely to receive proper surgery (27.3% vs 47.9%, p<0.001) or chemotherapy (42.4% vs 53.6%, p<0.001). There were statistically significant trends between increasing SES and the likelihood of overall treatment plan adherence to the NCCN guidelines: SES-1=16.4%, SES-2=19.0%, SES-3=22.4%, SES-4=24.2% and SES-5=31.6% (p<0.001). Multivariate logistic regression analysis revealed that compared to SES-5, decreasing SES was independently predictive of a higher risk of non-standard overall care. CONCLUSIONS: For patients with early-stage ovarian cancer, low SES is a significant and independent predictor of deviation from the NCCN guidelines for surgery, chemotherapy, and overall treatment.
Asunto(s)
Adhesión a Directriz/estadística & datos numéricos , Neoplasias Glandulares y Epiteliales/economía , Neoplasias Glandulares y Epiteliales/terapia , Neoplasias Ováricas/economía , Neoplasias Ováricas/terapia , Adulto , Anciano , Anciano de 80 o más Años , California/epidemiología , Carcinoma Epitelial de Ovario , Femenino , Humanos , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Glandulares y Epiteliales/epidemiología , Neoplasias Glandulares y Epiteliales/patología , Neoplasias Ováricas/epidemiología , Neoplasias Ováricas/patología , Sistema de Registros , Estudios Retrospectivos , Clase Social , Adulto JovenRESUMEN
Uterine sarcomas are rare uterine malignancies that are difficult to diagnose preoperatively. Because of cases of disseminated sarcoma after laparoscopic hysterectomy, the role of power morcellators in gynecologic surgery has been questioned. Morcellation is an integral part of making laparoscopic surgery possible for the removal of large uterine leiomyomata, and the development of power morcellation has increased efficiency during these procedures. Minimally invasive surgery has demonstrated benefits that include improved pain control, decreased infection risk, and faster surgical recovery and return to work. In this review, we examine the risk of incidental sarcoma at the time of surgery, the quality of the data, the accuracy of clinical and radiologic predictors of uterine sarcoma, and the impact of morcellation on the prognosis of uterine sarcoma.
Asunto(s)
Sarcoma/cirugía , Neoplasias Uterinas/cirugía , Femenino , Procedimientos Quirúrgicos Ginecológicos/métodos , Humanos , Sarcoma/diagnóstico , Neoplasias Uterinas/diagnósticoRESUMEN
An accurate method for the measurement of carbon isotope ratios of steroids in human urine has been developed at the National Measurement Institute, Australia (NMIA) for the certification of a freeze-dried human urine reference material (CRM NMIA MX005). The method measures δ(13)C values by gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) analysis following hydrolysis, solvent extraction and high performance liquid chromatography (HPLC) purification. Reference δ(13)C values for testosterone metabolites etiocholanolone, androsterone, and endogenous reference compounds (ERCs) 11ß-hydroxyandrosterone and pregnanediol were determined, as well as information δ(13)C values for testosterone, epitestosterone, 11-oxoetiocholanolone, and a range of differences (Δ(13)C) between testosterone metabolites and ERCs. The measurement uncertainty was rigorously evaluated with expanded uncertainties for the reference δ(13)C values between 1.1 and 1.6 at the 95% coverage level.
Asunto(s)
Anabolizantes/orina , Isótopos de Carbono/orina , Certificación/normas , Doping en los Deportes , Liofilización/normas , Cromatografía de Gases y Espectrometría de Masas/normas , Sustancias para Mejorar el Rendimiento/orina , Detección de Abuso de Sustancias/normas , Testosterona/orina , Androsterona/análogos & derivados , Androsterona/orina , Australia , Biomarcadores/orina , Biotransformación , Calibración , Cromatografía Líquida de Alta Presión , Etiocolanolona/orina , Humanos , Hidrólisis , Valor Predictivo de las Pruebas , Pregnanodiol/orina , Control de Calidad , Estándares de Referencia , Reproducibilidad de los Resultados , Solventes/química , Detección de Abuso de Sustancias/métodos , IncertidumbreAsunto(s)
Antipsicóticos/efectos adversos , Clozapina/efectos adversos , Leucemia Linfocítica Crónica de Células B/inducido químicamente , Trastornos Psicóticos/tratamiento farmacológico , Esquema de Medicación , Femenino , Humanos , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológicoRESUMEN
Little is known about how the information presented in the informed consent process influences study outcomes among participants. This study examines the influence of informed consent content on reported baseline contraceptive knowledge and concerns among two groups of HIV-serodiscordant and seroconcordant HIV-positive couples enrolled in research projects at an HIV research center in Lusaka, Zambia. We found significant differences in the reporting of contraceptive knowledge and concerns between couples viewing consent materials that included detailed information about contraception and those viewing consent materials that lacked the detailed information. We conclude that the design of informed consent materials should strike a balance between ensuring that participants give truly informed consent and educating participants in ways that do not compromise the assessment of the impact of behavioral interventions.
Asunto(s)
Anticoncepción/métodos , Infecciones por VIH/psicología , Conocimientos, Actitudes y Práctica en Salud , Consentimiento Informado , Adolescente , Adulto , Humanos , Persona de Mediana Edad , Adulto Joven , ZambiaRESUMEN
Ion exchange is widely used for the recovery and removal of metals from process and waste streams in chemical process industries. The Na-form of strong-acid Purolite NRW-100 resin was used to recover Ni(II) from a simulated electroplating waste solution containing NiSO4, NH4Cl, NaH2PO4, and citrate. A set of mass balance equations that take into account possible aqueous complexation reactions was used to establish the pH diagram of Ni(II) species in the presence of anionic ligand citrate or phosphate. Experiments were performed as a function of initial solution pH (0.5-6.0), initial concentration of Ni(II) (0.85-11.9 mol/m3), and temperature (15-45 degrees C). It was shown that the amount of Ni(II) exchanged leveled off when the equilibrium pH was higher than around 2.5. The exchange isotherms obtained at various equilibrium pH values were well fitted by the Langmuir equation. The enthalpy of Ni(II) exchange was also evaluated based on the Langmuir constant. Finally, the kinetics of the present ion exchange process was analyzed.